Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience

In aggressive pituitary tumors (PT) showing local invasion or growth/recurrence despite multimodal conventional treatment, temozolomide (TMZ) is considered a further therapeutic option, while little data are available on peptide receptor radionuclide therapy (PRRT). We analyzed PRRT effectiveness, s...

Descripción completa

Detalles Bibliográficos
Autores principales: Giuffrida, G, Ferraù, F, Laudicella, R, Cotta, O R, Messina, E, Granata, F, Angileri, F F, Vento, A, Alibrandi, A, Baldari, S, Cannavò, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499924/
https://www.ncbi.nlm.nih.gov/pubmed/30939449
http://dx.doi.org/10.1530/EC-19-0065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499924/
https://www.ncbi.nlm.nih.gov/pubmed/30939449
http://dx.doi.org/10.1530/EC-19-0065

Ejemplares similares